Back Tuberculosis

ICAAC 2014: Attempt to Shorten Standard Tuberculosis Treatment Fails in REMoxTB Trial

Two 4-month treatment regimens containing moxifloxacin were less effective than the standard 6-month regimen for drug-sensitive tuberculosis (TB), even though they produced a more rapid decline in bacterial load, according to results from the REMoxTB trial, which were presented in a poster session at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC, and published simultaneously in the September 7 New England Journal of Medicine.

alt

Read more:

TAG Releases 2014 HIV, Hepatitis C, and Tuberculosis Pipeline Report

The Treatment Action Group (TAG) and HIV i-Base this week released the latest edition of their annual Pipeline Report, covering new therapies and related technologies for HIV, hepatitis C, and tuberculosis (TB), in conjunction with the 20th International AIDS Conference taking place this week in Melbourne, Australia.

alt

Read more:

WHO Announces Plan to Eliminate Tuberculosis in Low-incidence Countries

The World Health Organization (WHO) and the European Respiratory Society (ERS) last week introduced a new framework for the elimination of tuberculosis (TB) in more than 30 low-incidence countries, which includes most of Western Europe, the U.S., Canada, and Australia.

alt

Read more:

AIDS 2014: Novel PaMZ Tuberculosis Regimen Could Reduce Treatment Duration

A novel tuberculosis (TB) drug regimen could treat drug-sensitive and some forms of drug-resistant TB far more quickly than current standard therapy, according to findings from a Phase 2b trial presented today at the 20th International AIDS Conference (AIDS 2104) in Melbourne, Australia.

alt

Read more:

Delamanid for Tuberculosis Approved in Europe, New Drugs Under Study

The European Union recently approved the new anti-tuberculosis drug delamanid (Deltyba) for use in combination therapy for people with multidrug-resistant TB. In related news, the Stop TB Partnership announced that it will make another new drug, bedaquiline (Sirturo), available in more than 100 low- and middle-income countries.

alt

Read more: